Key result
Glioma cell P2Y(AC) receptors match rat platelet P2Y12 receptors pharmacologically and molecularly.
Why the study?
The pharmacological and molecular identity of the P2YAC receptor in C6-2B glioma cells relative to the platelet P2Y12 receptor was unclear.
Population
C6-2B glioma cells, human and rat platelets, 1321N1 astrocytoma cells expressing P2Y1 receptor
Comparison
P2T receptor antagonists AR-C78511, AR-C69581, AR-C70300 effects on receptor activity
Design
Preclinical pharmacological and molecular study
Authors
Loading...
Offers no immediate clinical guidance; extends P2Y12 characterization to glial models but requires human validation.
The P2YAC receptor in C6-2B glioma cells is pharmacologically and molecularly identical to the P2Y12 receptor in platelets.
Jin et al. (2001) studied this question. P(2T) receptor antagonists (AR-C78511, AR-C69581, AR-C70300) was evaluated on ADP-induced aggregation of washed human or rat platelets and inhibition of adenylyl cyclase. The P2Y(AC) receptor in C6-2B glioma cells is pharmacologically and molecularly identical to the P2Y12 receptor in rat platelets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: